Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
At SOHO 2025, Lorenzo Falchi, MD, highlighted the critical role of nurses in monitoring and educating patients on toxicities from novel lymphoma therapies.
Precision Supportive Care Centers Patient Preference in Oncology
Michelle Kirschner, MSN, RN, ACNP, APRN-BC, discusses how precision supportive care tailors interventions to patient needs.
Safety Management With Amivantamab Plus Lazertinib in NSCLC
Benjamin Besse, MD, PhD, shares AE management strategies with amivantamab/lazertinib in EGFR-positive NSCLC following CHRYSALIS-2 results.
Long-Term Care in ALK+ NSCLC
Panelists discuss how they approach long-term monitoring and follow-up care for patients who have ALK-positive+ patients disease to maintain optimal outcomes on stable therapy.
Treatment Transitions in ALK+ NSCLC
Panelists discuss how practice improvements and patient resources can be implemented to empower both health care providers and patients who have ALK-positive disease.
Adverse Events of Menin Inhibitors in AML: What Nurses Should Know
Ghayas C. Issa, MD, MS, discusses key adverse events of menin inhibitors in NPM1-mutated and KMT2Ar AML.
Proactive Nursing Care for PI3K and AKT Inhibitor Adverse Effects
Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.
Monitoring Severe Adverse Effects of Bispecifics in Multiple Myeloma
Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology.
Patient Education for Long-Term Success on ALK Inhibitor Therapy
Panelists discuss how patient education strategies support long-term treatment success, adherence, and shared decision-making.
Monitoring Strategies for ALK Inhibitor Therapy
Panelists discuss how they monitor and educate patients on ALK inhibitor side adverse effects while equipping nursing staff to manage toxicities proactively.
Why Step-Up Dose With Bispecific Antibodies?
Karolina Faysman, NP, explains how step-up dosing is used to reduce CRS and ICANS with bispecific antibodies in multiple myeloma.
Nurses, APPs Critical to Getting Oncology Patients Newer Therapies
The role of nurses and APPs is crucial to ensuring patients with cancer can receive newer therapies, shares David A. Braun, MD, PhD.
Managing Infection Risk With Bispecific Antibodies in Myeloma
Nurse practitioner Beth Faiman shares strategies to reduce infection risk in patients receiving bispecific antibodies for multiple myeloma.
Precision Supportive Care Individualizes Patient Experience
Catering supportive care to the individual being treated helps better meet the needs of each patient, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.
Transitioning to Community Care With Multiple Myeloma
Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, outlines best practices for safely transitioning patients with multiple myeloma on bispecific antibodies to community care.
Patient Case – Treatment Considerations for ALK+ NSCLC
Panelists discuss how patient-specific factors, including brain metastases and drug tolerability, influence front-line ALK inhibitor selection.
Clinical Perspectives on Managing ALK Inhibitor Adverse Events
Panelists discuss how they manage adverse events associated with ALK inhibitors, comparing safety profiles and addressing unique patient concerns.
Current and Emerging ADCs Transforming Cancer Care
Kelsey Martin, APRN, AG-ACNP-BC, AOCNP, discusses current ADCs in breast, bladder, and lung cancer and highlights promising agents in development.
Simplifying Oral Oncolytic Adherence in Oncology Practice
Melissa Rikal, MSN, FNP-BC, AOCNP, shares strategies to help nurses improve adherence and patient education for oral oncolytic therapies.
How Nurses Can Assess and Manage Talquetamab Toxicities
Nurse practitioner Beth Faiman outlines nursing strategies to monitor, assess, and manage toxicities associated with talquetamab in multiple myeloma.
Key Considerations for First-Line ALK Inhibitor Treatment Selection
Panelists discuss how they guide first-line ALK inhibitor selection based on efficacy, tolerability, clinical data, and patient-specific considerations.
From Results to Therapy: Preparing Patients for ALK Inhibitor Therapy
Panelists discuss how they prepare patients for ALK inhibitor therapy following a confirmed ALK-positive result.
What Toxicities Are Common for ADCs Approved in Breast Cancer?
Melissa Rikal, MSN, FNP-BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.
Personalized Cancer Vaccines: Watching For Immune-Related, Vaccine AEs
David A. Braun, MD, PhD, explained that personalized cancer vaccines can be associated with toxicities typical of both vaccines and immunotherapies.
Expert Perspectives on Navigating Biomarker Testing for NSCLC Patients
Panelists discuss how strategic nursing coordination and effective communication support timely and comprehensive biomarker testing for newly diagnosed NSCLC patients.
Brief Overview & Key Insights: Current Treatment Practices for ALK+ NSCLC
Panelists discuss how evolving clinical advances and biomarker-driven therapies have transformed treatment practices and outcomes for patients with ALK+ NSCLC.
Helping Patients Weigh Extended Endocrine Therapy With the BCI
Michelle Kirschner, MSN, RN, ACNP, APRN-BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.
How to Give Subsequent Therapy for Older Patients With Breast Cancer on CDK4/6 Inhibitors
Treatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.
Nurses, APPs Key to AE Management as T-Cell Engagers Move Into Solid Tumors
Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.
Subcutaneous Daratumumab Provides Speedier Multiple Myeloma Treatment
Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says Stephanie Mompoint, APRN.
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
